## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO

ROBIN OSBORN,

Plaintiff,

V.

No. 23-cv-0212 GJF/JHR

NOVARTIS PHARMACEUTICALS CORPORATION,

Defendant.

## INITIAL SCHEDULING ORDER

This case is assigned to me for scheduling, case management, discovery and other nondispositive motions. The Federal Rules of Civil Procedure, as amended, as well as the Local Rules of the Court will apply to this lawsuit.

The parties, appearing through counsel or *pro se*, will "meet and confer" no later than Wednesday, May 31, 2023, to formulate a provisional discovery plan. FED. R. CIV. P. 26(f). The time allowed for discovery is generally 120 to 150 days. The parties will cooperate in preparing a *Joint Status Report and Provisional Discovery Plan ("JSR")* which follows the sample JSR available at the Court's web site. The blanks for suggested/proposed dates are to be filled in by the parties. Actual dates will be promulgated by order of the court shortly after entry of the JSR. Plaintiff, or Defendant in removed cases, is responsible for filing the JSR by Wednesday, June 28, 2023.

<sup>&</sup>lt;sup>1</sup> Pursuant to Administrative Order No. 06-173, the JSR replaces and supersedes the Provisional Discovery Plan and the Initial Pretrial Report, effective January 2, 2007. Please visit the Court's web site, <a href="www.nmcourt.fed.us">www.nmcourt.fed.us</a> to download the standardized *Joint Status Report and Provisional Discovery Plan* form.

Good cause must be shown and the Court's express and written approval obtained for any

modification of the dates in the scheduling order that issue from the JSR.

Initial disclosures under FED. R. CIV. P. 26(a)(1) shall be made within fourteen (14) days

of the meet-and-confer session.

A Rule 16 scheduling conference will be conducted by telephone on Friday July 14, 2023,

at 9:00 a.m. Counsel shall call the following telephone number to be connected to the

conference: (888) 278-0296 (access code: 9998216).

At the Rule 16 scheduling conference, counsel will be prepared to discuss discovery needs

and scheduling, all claims and defenses, the use of scientific evidence and whether a Daubert<sup>2</sup>

hearing is needed, initial disclosures, and the time of expert disclosures and reports under FED. R.

CIV. P. 26(a)(2). We will also discuss settlement prospects and alternative dispute resolution

possibilities and consideration of consent pursuant to 28 U.S.C. § 636(c). Client attendance is not

required. If service on all parties is not complete, plaintiff(s) appearing through counsel or pro se,

is (are) responsible for notifying all parties of the content of this order.

Pre-trial practice in this cause shall be in accordance with the foregoing.

UNITED STATES MAGISTRATE JUDGE

<sup>2</sup> Daubert v. Merrell Dow Pharmaceuticals, 509 U. S. 579 (1993).